Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS1001 plus chemotherapy versus placebo plus chemotherapy as first-line treatment for stage IV non-small cell lung cancer
CTR20181452Phase 3Completed
- Sponsor
- Cornerstone Pharmaceuticals
- Start
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sugemalimab in non-small cell lung cancer (NSCLC), sponsored by Cornerstone Pharmaceuticals. Started Dec 2018; status: completed.
02
Drugs
sugemalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20181452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181452.